Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel - Summary - MDSpire

Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel

Novel therapy for dry eye market

  • February 10, 2026

  • 2 min

Share

Objective:

To introduce Lacrifill®, a novel therapy for dry eye, to the European market following its CE mark approval.

Key Findings:
  • Dry eye disease affects up to 30% of the European population and poses challenges for surgical candidates.
  • Lacrifill® offers an individualized approach to dry eye management.
  • It is particularly beneficial for patients undergoing ocular surgical procedures.
Interpretation:

Lacrifill® is expected to improve ocular surface health and enhance surgical outcomes for patients with dry eye disease by stabilizing the ocular surface.

Limitations:
  • The long-term efficacy and safety of Lacrifill® beyond six months are not yet established.
  • Further studies may be needed to assess its impact on various patient demographics and long-term outcomes.
Conclusion:

The launch of Lacrifill® marks a significant advancement in dry eye management, particularly for surgical candidates.

Original Source(s)

Nordic Pharma Announces European Launch of Lacrifill® Canalicular Gel

  • February 10, 2026

Related Content

CSO Meeting 2026 Highlights Convergence of Innovation and Clinical Practice

More than 300 professionals gathered for three days of innovation, education, and collaboration, highlighting the latest advances in ophthalmic technology and clinical practice

  • May 12, 2026

  • 2 min
Survey: 96% of Optometrists Assess Smoking Status

Survey finds widespread smoking status screening among optometrists in Wales following national training requirements.

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.